FINALLY, A NEW DRUG SLOWS ALZHEIMER’S — BUT IS IT WORTH THE PRICE FOR MODEST BENEFIT?
The federal Food and Drug Administration has approved a new drug for Alzheimer’s disease that is the first to show clear evidence that it can slow the mind-robbing disease.
The drug — lecanemab, which will be sold under the brand name Leqembi — can slow the progression of Alzheimer’s in its early stages by several months.
Yet some experts are asking whether the modest benefit is worth the cost.
Though such a treatment has long been sought, experts caution that the drug is not a cure for Alzheimer’s disease, that it’s intended only for early-stage patients, requires IV doses every two weeks and has some safety concerns.
It’s not even clear just how noticeable that modest benefit will be.
Still, “It’s a landmark,” said Dr. Richard Hodes, director of the National Institute on Aging. “It’s not enough, but it’s encouraging that there’s something we can do.”
Some key things to know about Leqembi:
How does the new drug work?
The drug was developed, along with U.S. partner Biogen, by Japan’s Eisai, a Japanese pharmaceutical company that 25 years ago also produced the first treatment for Alzheimer’s symptoms.
It’s designed to target and clear away a sticky protein called beta-amyloid that builds up and forms brain-clogging plaques — a key hallmark of Alzheimer’s disease.
It targets a slightly different form of that amyloid, possibly explaining why it proved successful in a rigorous study even though many other amyloid-targeting drugs have failed, said Dr. Sam Gandy, an Alzheimer’s expert at New York’s Mount Sinai Hospital.
The FDA approved a similar drug called Aduhelm in 2021 even though studies never proved it really helped patients, a move that brought scathing criticism from a congressional investigation.
How effective is it?
In Eisai’s 18-month study of nearly 1,800 people, Leqembi appeared to delay earlystage patients from getting worse by about five months.
That was measured on an 18-point scale that tracks cognitive and functional abilities. People who got the drug still worsened but not as rapidly as those given dummy versions — a difference of nearly half a point on that scale by the study’s end.
Experts are divided over how meaningful a benefit that is. It might be hard for families to tell if a loved one’s decline has slowed, Gandy said.
Other experts said slowing the disease early on, when people still function well, is important even if it’s not that easy to spot.
“Several months with better cognition — what’s that worth to you?” Hodes said. “I think there you can get a strong argument: If I can interact with my family, be independent for months ... that’s a very meaningful outcome.”
What are known risks?
Like other amyloid-targeting medications, Leqembi can cause brain swelling or small brain bleeds. In Eisai’s study, 13% of drug recipients had swelling, and 17% has small brain bleeds.
The likely reason: Amyloid plaques usually form around nerve cells in the brain but sometimes the gunk gets inside blood vessels, too. Pulling amyloid out of those blood vessels can weaken them, making them leaky, Gandy said.
While the brain swelling and bleeds might cause only minimal symptoms, such as dizziness and vision problems, they occasionally can be severe — and several Leqembi users have died while taking the drug, including two who were on blood-thinning medications.
Eisai has said the deaths can’t be attributed to its Alzheimer’s drug.
Still, Gandy said the greatest risk of serious bleeding would be among Leqembi users who also take blood thinners, commonly used by older adults to prevent or treat strokes.
Patients also might experience temporary reactions after the infusions that can include fever, flu-like chills, nausea and blood pressure fluctuations.
Who is eligible?
The drug is only intended for people in the very early stages of Alzheimer’s who also have that tell-tale amyloid buildup.
The FDA warns doctors to use caution if they prescribe Leqembi to people who use blood thinners. Patients also will be urged to get brain scans several times over the course of treatment.
As patients gradually worsen, it’s not clear how long they should continue getting the twice-a-month IV infusions.
Study participants are being tracked for longer periods, and other research is exploring even earlier use — before people with amyloid buildup show symptoms.
When will it be available?
Eisai says the drug should be available by Jan. 23, but most patients will likely have to wait months to get it.
That’s because health insurers are expected to scrutinize the drug’s effectiveness before deciding whether to cover it, if so for which patients and what testing to require to confirm they are good candidates.
And Medicare, which covers most people with Alzheimer’s, is not expected to pay for the drug until later this year. That’s because the plan for seniors pays only for Alzheimer’s drugs that have received full approval from the FDA — while the agency granted Leqembi’s approval using a shortcut based on preliminary study results. The FDA is set to review that larger 18-month study soon, in anticipation of full approval later this year.
How much will the drug cost?
The IV drug will cost about $26,500 for a typical year’s worth of treatment. If insurers cover it, most people won’t pay anywhere near that much — though people with insurance that requires them to shoulder a larger portion of their drug costs could pay thousands a year.